Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korea FDA Raids Chong Kun Dang On Kickback Allegations

This article was originally published in PharmAsia News

Executive Summary

SEOUL - Reflecting the Korean government's bid to crack down on medical kickbacks, Korea FDA investigators, armed with a search and seizure warrant, raided the headquarters and four branches of Chong Kun Dang Pharmaceutical following allegations that the pharma is offering illegal rebates ahead of the launch of the anti-rebate law Nov. 28
Advertisement

Related Content

Korea Trade Commission Launches Kickback Probes Of Pharmaceutical Firms Following Similar Action By Drug Regulators
Korea Trade Commission Launches Kickback Probes Of Pharmaceutical Firms Following Similar Action By Drug Regulators
South Korea's Health Ministry Unveils Provisions For November's Anti-rebate Law
South Korea's Health Ministry Unveils Provisions For November's Anti-rebate Law
Korean Drug Regulators Raid Roche Korea, Search For Evidence On Tamiflu Stockpiling
Advertisement
UsernamePublicRestriction

Register

SC073463

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel